Corcept Therapeutics Incorporated Looks to Continue to Trade Above its Annual-High Share Price Today

April 6, 2022 09:17:21

Corcept Therapeutics Incorporated (NASDAQ:CORT) traded at a new 52-week high today of $31.14. So far today approximately 93.8 million shares have been exchanged, as compared to an average 30-day volume of 957,000 shares.

Corcept Therapeutics Incorporated (NASDAQ:CORT) defies analysts with a current price ($24.22) 2.3% above its average consensus price target of $23.67.

In the past 52 weeks, shares of Corcept Therapeutics Incorporated have traded between the current low of $4.13 and a high of $25.50 and is now at $24.22.

Corcept Therapeutics Inc is engaged in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer